CheckMate 078: Patient-Reported Outcomes (PROs) With Nivolumab vs Docetaxel in Advanced Non-Small Cell Lung Cancer (NSCLC)

被引：0
作者：
Wu, Y. [1 ,2 ]
Chang, J. [3 ]
Zhang, L. [4 ]
Tu, H. [1 ,2 ]
Wu, L. [5 ]
Feng, J. [6 ]
Lu, S. [7 ]
Zhou, C. [8 ]
Wang, J. [9 ,10 ]
Mok, T. [11 ]
Taylor, F. [12 ]
Mossman, B. [12 ]
Penrod, J. [13 ]
Lawrance, R. [14 ]
Blum, S. [13 ]
Wang, P. F. [13 ]
Cheng, Y. [15 ]
机构：
[1] Guangdong Gen Hosp, Guangdong Lung Canc Inst, Guangzhou, Guangdong, Peoples R China
[2] Guangdong Acad Med Sci, Guangzhou, Guangdong, Peoples R China
[3] Fudan Univ, Shanghai Canc Ctr, Shanghai, Peoples R China
[4] Sun Yat Sen Univ, Guangzhou, Guangdong, Peoples R China
[5] Hunan Canc Hosp, Changsha, Hunan, Peoples R China
[6] Jiangsu Canc Hosp, Nanjing, Jiangsu, Peoples R China
[7] Shanghai Jiao Tong Univ Shanghai, Shanghai Chest Hosp, Shanghai Lung Canc Ctr, Shanghai, Peoples R China
[8] Shanghai Pulm Hosp, Shang, Peoples R China
[9] Chinese Acad Med Sci, Natl Canc Ctr, Natl Clin Res Ctr Canc, Canc Hosp, Beijing, Peoples R China
[10] Peking Union Med Coll, Beijing, Peoples R China
[11] Chinese Univ Hong Kong, Shatin, Hong Kong, Peoples R China
[12] Adelphi Values, Boston, MA USA
[13] Bristol Myers Squibb, Princeton, NJ USA
[14] Adelphi Values, Bollington, England
[15] Jilin Canc Hosp, Changchun, Jilin, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2018年 / 13卷 / 12期
关键词：
Advanced NSCLC; Nivolumab; Docetaxel; Patient-Reported Outcomes;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
OA10
引用
收藏
页码：S1047 / S1048
页数：2
相关论文
共 50 条
  • [41] Nivolumab in Non-Small Cell Lung Cancer (NSCLC): The Real-Life Data
    Dudnik, Elizabeth
    Moskovitz, Mor
    Daher, Sameh
    Shamai, Sivan
    Hanovich, Ekaterina
    Shechtman, Yelena
    Abu-Amna, Mahmoud
    Zer, Alona
    Wollner, Mira
    Bar, Jair
    Merimsky, Ofer
    Cyjon, Arnold
    Shochat, Tzippy
    Peled, Nir
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S417 - S418
  • [42] Nivolumab in Non-Small Cell Lung Cancer (NSCLC): A Real-Life Study
    Reis, D.
    Mendes, A.
    China, N.
    Dias, M.
    Coutinho, D.
    Silva, E.
    Campainha, S.
    Costa, T.
    Conde, S.
    Barroso, A.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S975 - S976
  • [43] Meta-Analysis of Atezolizumab vs Docetaxel in Non-Small Cell Lung Cancer Treatment Outcomes
    Fu, Yingya
    Xue, Guojuan
    ALTERNATIVE THERAPIES IN HEALTH AND MEDICINE, 2023, 29 (06) : 128 - 133
  • [44] Nivolumab, a new hope in non-small cell lung cancer
    Flippot, Ronan
    Fallet, Vincent
    Besse, Benjamin
    Massard, Christophe
    Wislez, Marie
    Vignot, Stephane
    BULLETIN DU CANCER, 2015, 102 (12) : 1046 - 1052
  • [45] Combination of immunotherapy with targeted therapies in advanced non-small cell lung cancer (NSCLC)
    Moya-Horno, Irene
    Viteri, Santiago
    Karachaliou, Niki
    Rosell, Rafael
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2018, 10
  • [46] Nivolumab and brain metastases in patients with advanced non-squamous non-small cell lung cancer
    Crino, Lucio
    Bronte, Giuseppe
    Bidoli, Paolo
    Cravero, Paola
    Minenza, Elisa
    Cortesi, Enrico
    Garassino, Marina C.
    Proto, Claudia
    Cappuzzo, Federico
    Grossi, Francesco
    Tonini, Giuseppe
    Sarobba, Maria Giuseppina
    Pinotti, Graziella
    Numico, Gianmauro
    Samaritani, Riccardo
    Ciuffreda, Libero
    Frassoldati, Antonio
    Bregni, Marco
    Santo, Antonio
    Piantedosi, Francovito
    Illiano, Alfonso
    De Marinis, Filippo
    Tamberi, Stefano
    Giannarelli, Diana
    Delmonte, Angelo
    LUNG CANCER, 2019, 129 : 35 - 40
  • [47] Gender Differences in Clinical Course and Patient-Reported Outcomes among Patient with Early-Stage Non-Small Cell Lung Cancer
    Li, C.
    Zhou, H.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S419 - S419
  • [48] Duration of nivolumab for pretreated, advanced non-small-cell lung cancer
    Geier, Margaux
    Descourt, Renaud
    Corre, Romain
    Leveiller, Guillaume
    Lamy, Regine
    Goarant, Eric
    Bizec, Jean-Louis
    Bernier, Cyril
    Quere, Gilles
    Amrane, Karim
    Gaye, Elisabeth
    Lucia, Francois
    Burte, Emilie
    Chouaid, Christos
    Robinet, Gilles
    CANCER MEDICINE, 2020, 9 (19): : 6923 - 6932
  • [49] Docetaxel (Taxotere®):: Current clinical development in non-small cell lung cancer (NSCLC)
    Manegold, C
    MEDIZINISCHE KLINIK, 1998, 93 (09) : A16 - A21
  • [50] Impact of lorlatinib on patient-reported outcomes in patients with advanced ALK-positive or ROS1-positive non-small cell lung cancer
    Peters, Solange
    Shaw, Alice T.
    Besse, Benjamin
    Felip, Enriqueta
    Solomon, Benjamin J.
    Soo, Ross A.
    Bearz, Alessandra
    Gadgeel, Shirish M.
    Lin, Chia-Chi
    Kao, Steven
    Seto, Takashi
    Masters, Elizabeth T.
    Abbattista, Antonello
    Clancy, Jill S.
    Thurm, Holger
    Reisman, Arlene
    Peltz, Gerson
    Camidge, D. Ross
    LUNG CANCER, 2020, 144 : 10 - 19
12345